MCID: DFF005
MIFTS: 56

Diffuse Large B-Cell Lymphoma

Categories: Rare diseases, Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Diffuse Large B-Cell Lymphoma

MalaCards integrated aliases for Diffuse Large B-Cell Lymphoma:

Name: Diffuse Large B-Cell Lymphoma 38 12 53 15 73
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified 73
Large B-Cell Diffuse Lymphoma 76
Dlbcl 53

Classifications:



External Ids:

Disease Ontology 12 DOID:0050745
ICD10 33 C83.3

Summaries for Diffuse Large B-Cell Lymphoma

NIH Rare Diseases : 53 Diffuse large B-cell lymphoma (DLBCL), a form of non-Hodgkin lymphoma, is the most common blood cancer. Lymphomas occur when cells of the immune system, known as B lymphocytes, grow and multiply uncontrollably. DLBCL occurs mostly in adults and is a fast-growing (aggressive) lymphoma. It can start in the lymph nodes or outside of the lymphatic system in the gastrointestinal tract, testes, thyroid, skin, breast, bone, or brain. Often, the first sign of DLBCL is a painless rapid swelling in the neck, armpit, abdomen, or groin caused by enlarged lymph nodes. For some people, the swelling may be painful. Other symptoms include night sweats, unexplained fevers, and weight loss. Treatment may differ depending on the location of the tumor and the subtype of lymphoma. For those who have advanced DCBCL and have not been treated previously, a combination of chemotherapy and the monoclonal antibody rituximab (Rituxan) (R-CHOP) may be tried.. In addition, as of October 2017, axicabtagene ciloleucel (brand name: Yescarta), a type of gene therapy, has been approved by the United States FDA to treat DCBCL that is not responding to at least two treatment attempts or has returned after being treated before. A stem cell transplant may also be an option if DLBCL returns or relapses.

MalaCards based summary : Diffuse Large B-Cell Lymphoma, also known as diffuse large b-cell lymphoma, not otherwise specified, is related to follicular lymphoma and burkitt lymphoma. An important gene associated with Diffuse Large B-Cell Lymphoma is MIR155 (MicroRNA 155
miR-155 can bind to the 3'-untranslated region(UTR) of hAT(1)R mRNAs and translationally repress the expression of this protein in vivo. Importantly, the translational repression mediated by miR-155 can be regulated by physiological stimuli.), and among its related pathways/superpathways are MicroRNAs in cancer and Parkinsons Disease Pathway. The drugs Cyclophosphamide and Cytarabine have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow.

Disease Ontology : 12 A B-cell lymphoma that is a cancer of B cells presenting as an aggressive tumour which can arise in virtually any part of the body.

Wikipedia : 76 Diffuse large B-cell lymphoma (DLBCL or DLBL) is a cancer of B cells, a type of white blood cell... more...

Related Diseases for Diffuse Large B-Cell Lymphoma

Diseases related to Diffuse Large B-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 288)
# Related Disease Score Top Affiliating Genes
1 follicular lymphoma 32.6 MIR106A MIR139 MIR149 MIR155
2 burkitt lymphoma 31.4 MIR127 MIR143 MIR145 MIR155
3 polymyositis 31.0 MIR127 MIR155 MIR21
4 leukemia, chronic lymphocytic 31.0 MIR143 MIR145 MIR155 MIR21 PEG10
5 thyroid cancer, nonmedullary, 1 30.9 HOTAIR HULC MIR155 MIR21
6 leiomyoma, uterine 30.7 MIR10A MIR139 MIR21
7 hepatocellular carcinoma 28.6 HOTAIR HULC MIR127 MIR139 MIR143 MIR145
8 lung cancer 28.2 HOTAIR MIR106A MIR139 MIR143 MIR145 MIR155
9 relapsed/refractory diffuse large b-cell lymphoma 12.7
10 primary cutaneous diffuse large b-cell lymphoma, leg type 12.6
11 epstein-barr virus-positive diffuse large b-cell lymphoma of the elderly 12.6
12 diffuse large b-cell lymphoma of the central nervous system 12.6
13 diffuse large b-cell lymphoma with chronic inflammation 12.5
14 gray zone lymphoma 12.1
15 t-cell/histiocyte rich large b cell lymphoma 11.8
16 richter's syndrome 11.6
17 primary mediastinal b-cell lymphoma 11.6
18 b-cell lymphomas 11.5
19 lymphoma 11.5
20 mediastinal gray zone lymphoma 11.4
21 reticulosarcoma 11.4
22 plasmablastic lymphoma 11.0
23 primary mediastinal large b-cell lymphoma 11.0
24 intravascular large b-cell lymphoma 11.0
25 primary central nervous system lymphoma 10.9
26 esophagus squamous cell carcinoma 10.8 HOTAIR MIR145
27 ovarian serous carcinoma 10.7 MIR143 MIR145 MIR21
28 esophagus adenocarcinoma 10.7 MIR143 MIR145 MIR21
29 ovarian epithelial cancer 10.7 HOTAIR HULC MIR127
30 kidney cancer 10.6 HOTAIR MIR106A MIR21
31 lymphoma, hodgkin, classic 10.6
32 alk-positive large b-cell lymphoma 10.5
33 osteogenic sarcoma 10.5 HOTAIR HULC PANDAR
34 lymphoma, mucosa-associated lymphoid type 10.5
35 hepatitis 10.5
36 leukemia 10.5
37 clear cell renal cell carcinoma 10.4 MIR145 MIR21 PANDAR
38 peripheral t-cell lymphoma 10.4
39 astrocytoma 10.4 HOTAIR MIR106A MIR21
40 pancreatic ductal adenocarcinoma 10.4 HOTAIR MIR143 MIR145 MIR155 MIR21
41 aging 10.4
42 mediastinitis 10.4
43 angioimmunoblastic t-cell lymphoma 10.4
44 pituitary adenoma 10.4 HOTAIR MIR149
45 mantle cell lymphoma 10.4
46 leukemia, chronic lymphocytic 2 10.3
47 hepatitis c 10.3
48 leukemia, b-cell, chronic 10.3
49 endotheliitis 10.3
50 lymphoplasmacytic lymphoma 10.3

Graphical network of the top 20 diseases related to Diffuse Large B-Cell Lymphoma:



Diseases related to Diffuse Large B-Cell Lymphoma

Symptoms & Phenotypes for Diffuse Large B-Cell Lymphoma

Drugs & Therapeutics for Diffuse Large B-Cell Lymphoma

Drugs for Diffuse Large B-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 530)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
2
Cytarabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 147-94-4 6253
3
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
4
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
5
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
6
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2068-78-2, 57-22-7 5978
7
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
8
Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
9
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-02-2 5743
10
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
11
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
12
Ifosfamide Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 3778-73-2 3690
13
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
14
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
15
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 59917-39-4, 53643-48-4 40839
16
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
17
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 5754
18
Epirubicin Approved Phase 4,Phase 3,Phase 2,Not Applicable 56420-45-2 41867
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
20
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
21
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 31703
22 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
25 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 BB 1101 Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
40 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Dexamethasone acetate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1177-87-3
42 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49
Isophosphamide mustard Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 0
50 Methylprednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 1312)
# Name Status NCT ID Phase Drugs
1 LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
2 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
3 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
4 A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma Recruiting NCT03579082 Phase 4 Decitabine
5 Treatment of Diffuse Large B Cell Lymphoma Recruiting NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
6 Treatment of Relapsed /Refractory Diffuse Large B Cell Lymphoma Recruiting NCT03376958 Phase 4 Apatinib
7 Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma Recruiting NCT03513601 Phase 4 (R)-CHOP regimen;(R)-CVP regimen
8 Reduced Chemotherapy in Low Risk DLBCL Recruiting NCT02752815 Phase 4 Rituximab;Cyclophosphamide;Epirubicin;Vincristine;Prednisone
9 Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients Unknown status NCT00846157 Phase 3
10 Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP. Unknown status NCT01805557 Phase 2, Phase 3 R-DHAP;BR-DHAP
11 MabionCD20® Compared to MabThera® in Lymphoma Patients Unknown status NCT02617485 Phase 3 Rituximab;Doxorubicin;Vincristine;Cyclophosphamide;prednisone
12 Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma Unknown status NCT00499018 Phase 3 Rituximab;Ciclofosfamide;Doxorubicina;Vincristina;Prednisone;Pegfilgrastim;Mitoxantrone;ARA-C;Lenograstim;BCNU;ARA-C;VP-16;Ciclofosfamide;Doxorubicina;Vincristina
13 30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy Unknown status NCT01156259 Phase 3
14 Study Comparing the Zevalin Regimen With no Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R Unknown status NCT00322218 Phase 3 Zevalin Therapeutic Regimen
15 TREatment of degeNerative and Neoplastic Diseases With Rituximab Unknown status NCT01277172 Phase 2, Phase 3
16 Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOP Unknown status NCT01210287 Phase 2, Phase 3 nucleoside analog reverse transcriptase inhibitor
17 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
18 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
19 Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00028717 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
20 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
21 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
22 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
23 Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00003815 Phase 3 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisolone;vincristine sulfate
24 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
25 Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
26 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
27 High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003578 Phase 3 CHOP regimen;carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisone;vincristine sulfate
28 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
29 A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) Completed NCT01287741 Phase 3 Rituximab;Obinutuzumab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone
30 Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy Completed NCT00790036 Phase 3 Everolimus;Everolimus Placebo
31 A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a Completed NCT01724021 Phase 3 Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP);Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP);Bendamustine;Rituximab;Rituximab;Rituximab;Rituximab
32 ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1 Completed NCT00140595 Phase 3 rituximab;doxorubicin;cyclophosphamide
33 R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma Completed NCT00144755 Phase 3 Darbepoetin alfa
34 A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib Completed NCT01324596 Phase 3 Intravenous;Bortezomib
35 A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma Completed NCT01649856 Phase 3 CHOP;rituximab [MabThera/Rituxan];rituximab [MabThera/Rituxan]
36 ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma Completed NCT00169130 Phase 2, Phase 3 doxorubicin;cyclophosphamide
37 Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma Completed NCT02268045 Phase 3
38 R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma Completed NCT00137995 Phase 3 Rituximab;Etoposide;Carboplatine;Ifosfamide + Mesna;Cisplatine;Cytosine Arabinoside;Dexamethasone;BCNU;Etoposide;Cytarabine;Melphalan
39 R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL Completed NCT01148446 Phase 3 Cyclophosphamide;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone;Prednisone;Epirubicin;Vinblastine;Rituximab;G-CSF
40 Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma Completed NCT00052923 Phase 3 carmustine;cyclophosphamide;etoposide
41 Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma Completed NCT01014208 Phase 3 OFATUMUMAB + DHAP;RITUXIMAB + DHAP
42 MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma Completed NCT01987505 Phase 3 Rituximab
43 Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma Completed NCT01459887 Phase 3 CHOP combined with CMAB304;CHOP, CMAB304
44 Two Different Methods of Collecting Stem Cells For an Autologous Stem Cell Transplant in Treating Patients With Diffuse Large Cell Lymphoma Completed NCT00566228 Phase 3
45 Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL. Completed NCT00355199 Phase 3 Rituximab-HDS;Rituximab-CHOP
46 Zevalin-beam for Aggressive Lymphoma Completed NCT00491491 Phase 3 ibritumomab tiuxetan
47 A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13 Completed NCT00400478 Phase 3 Rituximab
48 A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE) Completed NCT00719472 Phase 3 Rituximab;CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone);CVP (cyclophosphamide, vincristine, prednisone);Analgesic/antipyretic and antihistamine drugs
49 PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin Completed NCT00332202 Phase 3 enzastaurin;placebo
50 Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00012051 Phase 3 carmustine;cisplatin;cytarabine;dexamethasone;etoposide;ifosfamide;melphalan;methotrexate

Search NIH Clinical Center for Diffuse Large B-Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Diffuse Large B-Cell Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Diffuse Large B-Cell Lymphoma

Anatomical Context for Diffuse Large B-Cell Lymphoma

MalaCards organs/tissues related to Diffuse Large B-Cell Lymphoma:

41
B Cells, Bone, Bone Marrow, T Cells, Breast, Liver, Testes

Publications for Diffuse Large B-Cell Lymphoma

Articles related to Diffuse Large B-Cell Lymphoma:

(show top 50) (show all 1988)
# Title Authors Year
1
An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma. ( 29934061 )
2018
2
A Rare Manifestation of Primary Bone Lymphoma: Solitary Diffuse Large B-Cell Lymphoma of the Little Finger. ( 29398333 )
2018
3
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma. ( 29416618 )
2018
4
Extranodal diffuse large B-cell lymphomas: A retrospective case series and review of the literature. ( 29721249 )
2018
5
Clinical Response to CHOP vs. R-CHOP in Adult Patients with Diffuse Large B-Cell Lymphomas ( 29801398 )
2018
6
Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: Results of a phase II study. ( 29956350 )
2018
7
Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin. ( 29966970 )
2018
8
Computer-driven quantitative image analysis in the assessment of tumor cell and T cell features in diffuse large B cell lymphomas. ( 29362889 )
2018
9
High frequency and prognostic value of<i>MYD88</i>L265P mutation in diffuse large B-cell lymphoma with R-CHOP treatment. ( 29403563 )
2018
10
Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma. ( 29419431 )
2018
11
Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy. ( 29899297 )
2018
12
Composite cutaneous lymphoma of diffuse large B-cell lymphoma-leg type and subcutaneous panniculitis-like T-cell lymphoma. ( 29851123 )
2018
13
Primary Liver Diffuse Large B-Cell Lymphoma following Complete Response for Hepatitis C Infection after Direct Antiviral Therapy. ( 29393087 )
2018
14
The Diving Bell and the Butterfly Revisited: A Fatal Case of Locked-in Syndrome in a Man With Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. ( 29623003 )
2018
15
Spontaneous Regression of Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type. ( 29508000 )
2018
16
Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm. ( 29978453 )
2018
17
Concurrent mucosa-associated lymphoid tissue lymphoma with diffuse large B-cell lymphoma transformation and Hodgkin lymphoma of the neck. ( 29427189 )
2018
18
Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. ( 29413279 )
2018
19
De Novo CD5-Positive Primary Gastric Diffuse Large B-Cell Lymphoma Coexpressing MYC and BCL6: Towards a Proper Subset of Double-Hit, Triple-Hit and, Maybe, Quadruple-Hit B-Cell Lymphomas? ( 29399573 )
2018
20
Fatal cardiac arrhythmia caused by tumor lysis in a patient with diffuse large B-cell lymphoma upon start of R-CHOP. ( 29531724 )
2018
21
Burkitt lymphoma and diffuse large B-cell lymphoma: a unique case of a composite lymphoma of different clonal origin. ( 28583033 )
2018
22
Anti-ZIC4 associated paraneoplastic cerebellar degeneration in a patient with both diffuse large B-cell lymphoma and incidental smoldering multiple myeloma. ( 29249374 )
2018
23
Teaching NeuroImages: Presentation of diffuse large B-cell lymphoma with bilateral sequential oculomotor neuropathy. ( 29967210 )
2018
24
Lymphomatoid Papulosis (LyP) Associated with Diffuse Large B-cell Lymphoma and Cutaneous Anaplastic Large Cell Lymphoma: LyP as a Haematological Malignancy-related Dermadrome. ( 29796688 )
2018
25
Numb chin syndrome as a presenting symptom of diffuse large B-cell lymphoma with secondary myelofibrosis. ( 29930179 )
2018
26
Complete response of diffuse large B-cell lymphoma after direct-acting antiviral therapy for hepatitis C virus. ( 29432921 )
2018
27
Transmission of diffuse large B cell lymphoma by an allogeneic stem-cell transplant. ( 29976740 )
2018
28
Secondary Cutaneous Epstein-Barr Virus-associated Diffuse Large B-cell Lymphoma with Hodgkin/Reed-Sternberg-like Cells in a Patient with Angioimmunoblastic T-cell Lymphoma. ( 29956714 )
2018
29
A B-cell-associated gene signature classification of diffuse large B-cell lymphoma by NanoString technology. ( 29967255 )
2018
30
Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.<i>Blood</i>. 2017;130(16):1800-1808. ( 29437609 )
2018
31
Chemotherapy is administered to a minority of hospitalized patients with diffuse large B-cell lymphoma and is associated with less likelihood of death during hospitalization. ( 29438924 )
2018
32
Diffuse large B-cell lymphoma chemotherapy reveals a combined immunodeficiency syndrome in cartilage hair hypoplasia. ( 29688570 )
2018
33
Negative effect of hepatitis in overall and progression-free survival among patients with diffuse large B-cell lymphoma. ( 29977329 )
2018
34
Geriatric nutritional risk index as a prognostic factor in patients with diffuse large B cell lymphoma. ( 29427185 )
2018
35
Erratum: Epperla N, Maddocks KJ, Salhab M, et al. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional &amp;quot;hits&amp;quot; and outcomes with subsequent therapy. Cancer. 2017;123:4411-4418. ( 29406586 )
2018
36
Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy. ( 29966461 )
2018
37
Comprehensive analysis of differentially expressed profiles of lncRNAs and mRNAs reveals ceRNA networks in the transformation of diffuse large B-cell lymphoma. ( 29963159 )
2018
38
Epstein-Barr Virus-Positive CD20- and CD45-Negative Diffuse Large B-Cell Lymphoma: A Diagnostic Challenge. ( 29968492 )
2018
39
Synchronous Occurrence of Mycosis Fungoides, Diffuse Large B cell Lymphoma and Acute Myeloid Leukemia: A Report of Two Cases. ( 29321428 )
2018
40
Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL). ( 29975624 )
2018
41
Ratio of Immune Response to Tumor Burden Predicts Survival Via Regulating Functions of Lymphocytes and Monocytes in Diffuse Large B-Cell Lymphoma. ( 29428948 )
2018
42
Circulating MicroRNAs as Biomarkers in Diffuse Large B-cell Lymphoma: A Pilot Prospective Longitudinal Clinical Study. ( 29977116 )
2018
43
Pleural effusion at diagnosis predicts extremely poor outcomes in patients with diffuse large B-cell lymphoma harbouring MYC rearrangement. ( 29974930 )
2018
44
Some diffuse large B-cell lymphomas (DLBCLs) present with clone-dependent TTF-1 positivity. ( 29393528 )
2018
45
Targetable Metabolic Vulnerability in Diffuse Large B-Cell Lymphoma. ( 29397369 )
2018
46
Tumor-associated neutrophils correlate with poor prognosis in diffuse large B-cell lymphoma patients. ( 29977076 )
2018
47
High 18F-fluorodeoxyglucose uptake in primary bilateral adrenal diffuse large B-cell lymphomas with nongerminal center B-cell phenotype: A case report. ( 29703006 )
2018
48
Systemic diffuse large B-cell lymphoma masquerading as neovascular glaucoma. ( 29380792 )
2018
49
Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. ( 29955182 )
2018
50
Over-activated PD-1/PD-L1 axis facilitates the chemoresistance of diffuse large B-cell lymphoma cells to the CHOP regimen. ( 29435074 )
2018

Variations for Diffuse Large B-Cell Lymphoma

Cosmic variations for Diffuse Large B-Cell Lymphoma:

9
(show top 50) (show all 588)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM3276983 ZFHX3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,diffuse large B cell lymphoma c.745G>A p.G249S 16:72959401-72959401 7
2 COSM6940532 YES1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.1474C>T p.P492S 18:724582-724582 7
3 COSM96797 XPO1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.1711G>A p.E571K 2:61492337-61492337 7
4 COSM6987097 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5137C>T p.R1713C 16:2088116-2088116 7
5 COSM6987331 TSC2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.5197A>G p.T1733A 16:2088263-2088263 7
6 COSM10834 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.711G>A p.M237I 17:7674252-7674252 7
7 COSM10659 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.817C>T p.R273C 17:7673803-7673803 7
8 COSM43967 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.751A>T p.I251F 17:7674212-7674212 7
9 COSM10656 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.742C>T p.R248W 17:7674221-7674221 7
10 COSM43684 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.720T>G p.S240R 17:7674243-7674243 7
11 COSM10648 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.524G>A p.R175H 17:7675088-7675088 7
12 COSM44057 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.517G>C p.V173L 17:7675095-7675095 7
13 COSM10742 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.578A>G p.H193R 17:7674953-7674953 7
14 COSM10722 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.853G>A p.E285K 17:7673767-7673767 7
15 COSM44327 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.518T>C p.V173A 17:7675094-7675094 7
16 COSM43947 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.614A>G p.Y205C 17:7674917-7674917 7
17 COSM10758 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.659A>G p.Y220C 17:7674872-7674872 7
18 COSM10662 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.743G>A p.R248Q 17:7674220-7674220 7
19 COSM43936 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.857A>T p.E286V 17:7673763-7673763 7
20 COSM6932 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.733G>A p.G245S 17:7674230-7674230 7
21 COSM43970 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.380C>A p.S127Y 17:7675232-7675232 7
22 COSM45416 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.524G>C p.R175P 17:7675088-7675088 7
23 COSM10687 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.527G>A p.C176Y 17:7675085-7675085 7
24 COSM10690 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.473G>A p.R158H 17:7675139-7675139 7
25 COSM44948 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.526T>C p.C176R 17:7675086-7675086 7
26 COSM45627 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.486C>T p.I162I 17:7675126-7675126 7
27 COSM10996 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.511G>T p.E171* 17:7675101-7675101 7
28 COSM10813 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.394A>G p.K132E 17:7675218-7675218 7
29 COSM44338 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.845G>A p.R282Q 17:7673775-7673775 7
30 COSM11196 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.734G>T p.G245V 17:7674229-7674229 7
31 COSM44821 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.412G>A p.A138T 17:7675200-7675200 7
32 COSM10645 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.527G>T p.C176F 17:7675085-7675085 7
33 COSM43899 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.434T>C p.L145P 17:7675178-7675178 7
34 COSM11287 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.839G>T p.R280I 17:7673781-7673781 7
35 COSM44171 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.840A>T p.R280S 17:7673780-7673780 7
36 COSM43850 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.659A>C p.Y220S 17:7674872-7674872 7
37 COSM43559 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.517G>T p.V173L 17:7675095-7675095 7
38 COSM10704 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.844C>T p.R282W 17:7673776-7673776 7
39 COSM43896 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.818G>C p.R273P 17:7673802-7673802 7
40 COSM10647 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.404G>T p.C135F 17:7675208-7675208 7
41 COSM43903 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.470T>G p.V157G 17:7675142-7675142 7
42 COSM44535 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.761T>A p.I254N 17:7674202-7674202 7
43 COSM44002 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.577C>G p.H193D 17:7674954-7674954 7
44 COSM45035 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.761T>G p.I254S 17:7674202-7674202 7
45 COSM44030 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.760A>G p.I254V 17:7674203-7674203 7
46 COSM10705 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.586C>T p.R196* 17:7674945-7674945 7
47 COSM43963 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.396G>C p.K132N 17:7675216-7675216 7
48 COSM43939 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.632C>T p.T211I 17:7674899-7674899 7
49 COSM10777 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.715A>G p.N239D 17:7674248-7674248 7
50 COSM43555 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.736A>G p.M246V 17:7674227-7674227 7

Copy number variations for Diffuse Large B-Cell Lymphoma from CNVD:

7 (show top 50) (show all 118)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13828 1 1 84900000 Loss Diffuse large b-cell lymphoma
2 17406 1 142600000 249250621 Gain Diffuse large b-cell lymphoma
3 20082 1 15300000 163800000 Gain Diffuse large b-cell lymphoma
4 38345 10 101900000 103000000 Gain Diffuse large b-cell lymphoma
5 38773 10 104900000 105800000 Gain Diffuse large b-cell lymphoma
6 38901 10 105800000 121700000 Loss Diffuse large b-cell lymphoma
7 40597 10 130600000 135534747 Loss Diffuse large b-cell lymphoma
8 43294 10 46100000 64500000 Loss Diffuse large b-cell lymphoma
9 48479 11 1 43500000 Gain Diffuse large b-cell lymphoma
10 51204 11 123900000 135006516 Loss Diffuse large b-cell lymphoma
11 53206 11 26100000 36400000 Loss Diffuse large b-cell lymphoma
12 55792 11 55700000 135006516 Gain Diffuse large b-cell lymphoma
13 64291 12 12600000 14800000 Gain CDKN1B Diffuse large b-cell lymphoma
14 70914 12 66000000 69800000 Gain MDM2 Diffuse large b-cell lymphoma
15 74343 13 104800000 110300000 Loss Diffuse large b-cell lymphoma
16 74383 13 105800000 109100000 Loss Diffuse large b-cell lymphoma
17 75387 13 19500000 55300000 Gain Diffuse large b-cell lymphoma
18 76712 13 35500000 75400000 Loss Diffuse large b-cell lymphoma
19 79280 13 68600000 115169878 Gain Diffuse large b-cell lymphoma
20 86223 14 55800000 61200000 Loss Diffuse large b-cell lymphoma
21 88116 14 84900000 107349540 Loss Diffuse large b-cell lymphoma
22 90236 15 20700000 102531392 Loss Diffuse large b-cell lymphoma
23 97251 16 1 34600000 Gain Diffuse large b-cell lymphoma
24 97373 16 1 7900000 Gain ABCA3 Diffuse large b-cell lymphoma
25 97375 16 1 7900000 Gain DCI Diffuse large b-cell lymphoma
26 97377 16 1 7900000 Gain E4F1 Diffuse large b-cell lymphoma
27 97379 16 1 7900000 Gain HAGH Diffuse large b-cell lymphoma
28 97381 16 1 7900000 Gain IGFALS Diffuse large b-cell lymphoma
29 97383 16 1 7900000 Gain MRPS34 Diffuse large b-cell lymphoma
30 97385 16 1 7900000 Gain NME3 Diffuse large b-cell lymphoma
31 97387 16 1 7900000 Gain NUBP2 Diffuse large b-cell lymphoma
32 97391 16 1 7900000 Gain RNPS1 Diffuse large b-cell lymphoma
33 99692 16 28100000 36600000 Loss Diffuse large b-cell lymphoma
34 102840 16 57400000 90354753 Gain Diffuse large b-cell lymphoma
35 102843 16 57400000 90354753 Loss Diffuse large b-cell lymphoma
36 104071 16 66700000 70800000 Gain DDX19 Diffuse large b-cell lymphoma
37 104073 16 66700000 70800000 Gain FUK Diffuse large b-cell lymphoma
38 104075 16 66700000 70800000 Gain SIAT4B Diffuse large b-cell lymphoma
39 106530 16 88700000 90354753 Gain Diffuse large b-cell lymphoma
40 106806 17 1 22200000 Loss Diffuse large b-cell lymphoma
41 111431 17 3600000 6800000 Loss TP53 Diffuse large b-cell lymphoma
42 120634 18 2900000 78077248 Gain Diffuse large b-cell lymphoma
43 121454 18 43500000 48200000 Gain Diffuse large b-cell lymphoma
44 121719 18 46400000 52000000 Gain BCL2 Diffuse large b-cell lymphoma
45 122173 18 53800000 56200000 Gain MALT1 Diffuse large b-cell lymphoma
46 123098 18 66800000 68700000 Loss Diffuse large b-cell lymphoma
47 123108 18 66900000 71300000 Gain Diffuse large b-cell lymphoma
48 127687 19 35500000 38300000 Gain KIRREL2 Diffuse large b-cell lymphoma
49 127689 19 35500000 38300000 Gain MLL4 Diffuse large b-cell lymphoma
50 127691 19 35500000 38300000 Gain NPHS1 Diffuse large b-cell lymphoma

Expression for Diffuse Large B-Cell Lymphoma

Search GEO for disease gene expression data for Diffuse Large B-Cell Lymphoma.

Pathways for Diffuse Large B-Cell Lymphoma

Pathways related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.83 MIR10A MIR143 MIR145 MIR155 MIR21
2 10.85 MIR106A MIR10A MIR127 MIR17HG

GO Terms for Diffuse Large B-Cell Lymphoma

Cellular components related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.17 MIR106A MIR10A MIR127 MIR139 MIR143 MIR155

Biological processes related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of blood vessel endothelial cell migration GO:0043537 9.56 MIR10A MIR155
2 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.55 MIR145 MIR21
3 activation of protein kinase B activity GO:0032148 9.54 MIR143 MIR21
4 negative regulation of smooth muscle cell proliferation GO:0048662 9.52 MIR143 MIR145
5 positive regulation of activated T cell proliferation GO:0042104 9.51 MIR155 MIR21
6 positive regulation of cardiac muscle hypertrophy GO:0010613 9.49 MIR155 MIR21
7 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.48 MIR143 MIR21
8 regulation of smooth muscle contraction GO:0006940 9.46 MIR143 MIR145
9 negative regulation of angiogenesis GO:0016525 9.46 MIR10A MIR143 MIR145 MIR21
10 negative regulation of cardiac muscle hypertrophy GO:0010614 9.43 MIR145 MIR21
11 angiotensin-activated signaling pathway GO:0038166 9.4 MIR143 MIR145
12 negative regulation of regulatory T cell differentiation GO:0045590 9.37 MIR155 MIR21
13 aorta smooth muscle tissue morphogenesis GO:0060414 9.32 MIR143 MIR145
14 regulation of phenotypic switching GO:1900239 9.26 MIR143 MIR145
15 gene silencing by miRNA GO:0035195 9.17 MIR106A MIR10A MIR143 MIR145 MIR155 MIR17HG
16 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 8.96 MIR143 MIR145

Molecular functions related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.17 MIR106A MIR10A MIR143 MIR145 MIR155 MIR17HG

Sources for Diffuse Large B-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....